Kate Therapeutics
Rob Fiorentino, MD, MPH is the VP Clinical Development at Kate Therapeutics since January 2022. Prior to that, Rob served as Senior Director, Immunology at The Janssen Pharmaceutical Companies of Johnson & Johnson from September 2019 to January 2022. Rob also held the position of Senior Director, Clinical Research & Development at REGENXBIO Inc. from May 2015 to September 2019, where Rob led clinical development teams for gene therapy programs. Earlier in their career, Rob worked at the FDA in various roles including Medical Team Leader in the Division of Gastroenterology and Inborn Errors Drug Products. Dr. Fiorentino holds a MPH from Harvard T.H. Chan School of Public Health and an MD from New York Medical College.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.